Avant Technologies Partner, Ainnova, Signs Pilot Program With Roche to Combat Diabetic Retinopathy
Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, has announced a strategic alliance with Roche and Salud 360 to launch a pilot program combating diabetic retinopathy in Costa Rica. The program will utilize Ainnova's AI technology and non-mydriatic fundus cameras to analyze retinal images for early detection of the disease.
The initiative targets Costa Rica, where diabetes affects 10.4% of adults, with 20-40% of diabetic patients developing diabetic retinopathy. The program aims to prevent blindness through early detection, as 80% of diabetes-related blindness cases are preventable with timely intervention. If successful, Avant and Ainnova plan to expand the program to the United States, Canada, and Europe through their joint venture, Ai-nova Acquisition Corp (AAC).
Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, ha annunciato un'alleanza strategica con Roche e Salud 360 per lanciare un programma pilota contro la retinopatia diabetica in Costa Rica. Il programma utilizzerà la tecnologia AI di Ainnova e le fotocamere per il fondo oculare non midriatiche per analizzare le immagini retiniche e consentire una diagnosi precoce della malattia.
L'iniziativa si concentra sulla Costa Rica, dove il diabete colpisce il 10,4% degli adulti, con il 20-40% dei pazienti diabetici che sviluppano retinopatia diabetica. Il programma ha l'obiettivo di prevenire la cecità attraverso una diagnosi precoce, poiché l'80% dei casi di cecità legati al diabete sono prevenibili con un intervento tempestivo. Se avrà successo, Avant e Ainnova pianificano di espandere il programma negli Stati Uniti, in Canada e in Europa attraverso la loro joint venture, Ai-nova Acquisition Corp (AAC).
Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, ha anunciado una alianza estratégica con Roche y Salud 360 para lanzar un programa piloto que combate la retinopatía diabética en Costa Rica. El programa utilizará la tecnología de inteligencia artificial de Ainnova y cámaras de fondo no midriáticas para analizar imágenes retinianas para la detección temprana de la enfermedad.
La iniciativa se dirige a Costa Rica, donde el 10,4% de los adultos sufre de diabetes, y entre el 20-40% de los pacientes diabéticos desarrollan retinopatía diabética. El programa tiene como objetivo prevenir la ceguera a través de la detección temprana, ya que el 80% de los casos de ceguera relacionados con la diabetes son prevenibles con intervención oportuna. Si tiene éxito, Avant y Ainnova planean expandir el programa a los Estados Unidos, Canadá y Europa a través de su empresa conjunta, Ai-nova Acquisition Corp (AAC).
Avant Technologies (OTCQB: AVAI)의 파트너인 Ainnova Tech는 Roche 및 Salud 360와 함께 코스타리카에서 당뇨병성 망막병증에 대응하는 파일럿 프로그램을 시작하기 위한 전략적 제휴를 발표했습니다. 이 프로그램은 Ainnova의 AI 기술과 비산동 형광 촬영 카메라를 활용하여 망막 이미지를 분석하고 질병의 조기 발견을 지원할 것입니다.
이 이니셔티브는 성인 중 10.4%가 당뇨병에 걸린 코스타리카를 대상으로 하며, 당뇨병 환자의 20-40%가 당뇨병성 망막병증을 앓고 있습니다. 이 프로그램은 조기 발견을 통해 실명을 예방하는 것을 목표로 하며, 당뇨병과 관련된 실명 사례의 80%는 적시 개입으로 예방할 수 있습니다. 성공할 경우 Avant 및 Ainnova는 Ai-nova Acquisition Corp (AAC)라는 합작 회사를 통해 미국, 캐나다 및 유럽으로 프로그램을 확장할 계획입니다.
Avant Technologies (OTCQB: AVAI) partenaire, Ainnova Tech, a annoncé une alliance stratégique avec Roche et Salud 360 pour lancer un programme pilote visant à lutter contre la rétinopathie diabétique au Costa Rica. Le programme utilisera la technologie IA d'Ainnova et des caméras de fondus non mydriatiques pour analyser les images rétiniennes afin de détecter la maladie à un stade précoce.
L'initiative cible le Costa Rica, où 10,4 % des adultes sont atteints de diabète, et entre 20 et 40 % des patients diabétiques développent une rétinopathie diabétique. Le programme vise à prévenir la cécité grâce à une détection précoce, car 80 % des cas de cécité liés au diabète sont évitables avec une intervention rapide. Si le programme réussit, Avant et Ainnova prévoient de l'étendre aux États-Unis, au Canada et en Europe via leur coentreprise, Ai-nova Acquisition Corp (AAC).
Avant Technologies (OTCQB: AVAI) Partner, Ainnova Tech, hat eine strategische Allianz mit Roche und Salud 360 angekündigt, um ein Pilotprogramm zur Bekämpfung der diabetischen Retinopathie in Costa Rica zu starten. Das Programm wird die AI-Technologie von Ainnova und nicht-mydriatische Funduskameras nutzen, um Netzhautbilder zu analysieren und die Krankheit frühzeitig zu erkennen.
Die Initiative richtet sich an Costa Rica, wo 10,4% der Erwachsenen an Diabetes leiden, und 20-40% der diabetischen Patienten entwickeln eine diabetische Retinopathie. Das Programm hat das Ziel, Blindheit durch frühzeitige Erkennung zu verhindern, da 80% der diabetesbedingten Blindheitsfälle mit rechtzeitiger Intervention vermeidbar sind. Wenn es erfolgreich ist, planen Avant und Ainnova, das Programm über ihr Joint Venture, Ai-nova Acquisition Corp (AAC), auf die Vereinigten Staaten, Kanada und Europa auszudehnen.
- Strategic partnership with global biotech leader Roche enhances market credibility
- Potential expansion to major markets (US, Canada, Europe) if pilot successful
- Addresses large market opportunity with 10.4% diabetes prevalence in initial market
- to pilot program stage with no guaranteed success
- Initial implementation restricted to single market (Costa Rica)
- No immediate revenue impact disclosed
LAS VEGAS, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Avant Technologies Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the company has entered into a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova’s cutting-edge technology.
The pilot program will initially be implemented in Costa Rica where diabetes affects about
According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country's adult population. To make matters worse, between
According to the World Health Organization,
Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova’s advanced technology and a patient-centered approach.
The pilot program will use non-mydriatic fundus cameras and artificial intelligence - developed by Ainnova Tech - to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests.
“At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system. By leveraging technology, we seek to improve lives, optimize diagnoses, and ensure that every patient has access to timely and effective treatment. With this model, we not only seek to address the problem of diabetic retinopathy, but also to establish a replicable path for other diseases that require innovative solutions,” said, Alvaro Soto, General Manager of Roche Central America, Caribbean, and Venezuela.
By implementing the pilot program in Costa Rica, this strategic alliance can take advantage of the country's robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists, guaranteeing comprehensive and timely care.
The results of this pilot program will be the basis for developing the model beyond our borders to benefit communities facing similar challenges in accessing medical care.
Vinicio Vargas, Chief Executive Officer of Ainnova Tech and member of AAC’s Board of Directors, emphasized, “We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally. Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions.”
[2] https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
FAQ
What is the purpose of Avant Technologies (AVAI) partnership with Roche?
Where will Avant Technologies (AVAI) initially implement its diabetic retinopathy program?
What technology will Avant Technologies (AVAI) use in the diabetic retinopathy program?
What are the expansion plans for Avant Technologies (AVAI) diabetic retinopathy program?
